Exploring the Safety, Effectiveness, and Cost-Effectiveness of a Chinese Patent Medicine (Fufang E'jiao Syrup) for Alleviating Cancer-Related Fatigue: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial. (April 2021)

• Record Type: Journal Article
• Authors: Song, Zhuo; Sun, Ling-yun; Gu, Shan-shan; Zhu, Xiao-shu; Lai, He-zheng; Lu, Fang; Cui, Ning; Li, Qiong-yang; Wu, Yu; Xu, Yun
• Is Part Of: Integrative cancer therapies. Volume 20(2021)
• Publication Date: 2021-04
• Subjects: cancer-related fatigue -- Fufang E'jiao syrup -- traditional Chinese medicine -- Chinese patent medicine -- randomized-controlled trial -- multicenter; Cancer -- Alternative treatment -- Periodicals; 616.99406
• DOI: 10.1177/15347354211002919
• Languages: English
• ISSNs: 1534-7354

Abstract

Objective: To provide higher level evidence on the benefits of a Chinese patent medicine (CPM) (Fufang E'jiao Syrup, FFEJS) for alleviating cancer-related fatigue (CRF), this article describes a protocol for a randomized controlled trial. Methods/design: We designed a double-blind, placebo-controlled stratified permuted block randomization clinical trial on CRF among 3 types of cancer in China. Participants will be equally allocated to FFEJS group or placebo group according to the randomization sequence and the hospitals they were enrolled at. Each patient will receive 20 ml of either the study formula FFEJS or a placebo formula, 3 times a day for 6 weeks. The follow-up period will be another 4 weeks for safety evaluation. The primary outcome is the difference in improvement of fatigue as measured with the Revised Piper Fatigue Scale-Chinese Version (RPFS-CV). Secondary outcomes include change in fatigue (measured by routine blood panel and hormones in peripheral blood) and QoL (measured by Edmonton symptom assessment scale and Functional Assessment of Cancer Therapy). Patient safety will be measured by liver, renal or cardiac damage, and the risk of FFEJS having a tumor promotion and progression effect will be monitored throughout this study. Cost-effectiveness will also be evaluated mainly by incremental cost per each quality-adjusted life year gained. Discussion: This article describes the study design of a CPM for CRF in patients with advanced cancer through exploring the effectiveness, safety, and cost-effectiveness of FFEJS. Trial registration: ClinicalTrials.gov, NCT04147312. Registered on 1 Sep 2019.